Dual gene therapy with SERCA1 and Kir2.1 abbreviates excitation without suppressing contractility

Area of Science:

• Cardiovascular Biology
• Molecular Cardiology
• Gene Therapy

Background:

• Heart failure presents with reduced contractility and delayed repolarization, increasing arrhythmia risk.
• Directly correcting delayed repolarization may worsen contractile dysfunction by limiting calcium cycling.
• A novel gene therapy is needed to shorten action potentials without negatively impacting cardiac contraction.

Purpose of the Study:

• To develop and test a dual gene therapy strategy to abbreviate cardiac excitation while preserving or improving contractility.
• To investigate the combined effects of SERCA1 and Kir2.1 gene coexpression on myocyte function.

Main Methods:

• Coexpression of the calcium ATPase SERCA1 and the potassium channel Kir2.1 in guinea pig cardiomyocytes.
• Assessment of myocyte calcium transients and action potential duration.
• In vivo evaluation of cardiac repolarization and contractile function.

Main Results:

• Coexpression led to larger calcium transients and shorter action potentials in myocytes.
• In vivo studies demonstrated abbreviated repolarization.
• Cardiac contractile function remained unimpaired following the dual gene therapy.

Conclusions:

• Dual gene therapy combining SERCA1 and Kir2.1 is a viable strategy to abbreviate cardiac repolarization without depressing contractility.
• This approach offers a flexible platform for gene therapy, enabling the combination of opposing or synergistic principles for tailored cardiac phenotypes.
• This research opens new avenues for managing heart failure and associated arrhythmias through precise genetic modulation.